These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 35065514)

  • 1. Profiling the regulatory interplay of BET bromodomains and Sirtuins in cancer cell lines.
    Järvenpää J; Rahnasto-Rilla M; Lahtela-Kakkonen M; Küblbeck J
    Biomed Pharmacother; 2022 Mar; 147():112652. PubMed ID: 35065514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bromodomains: Structure, function and pharmacology of inhibition.
    Ferri E; Petosa C; McKenna CE
    Biochem Pharmacol; 2016 Apr; 106():1-18. PubMed ID: 26707800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BET inhibition as a new strategy for the treatment of gastric cancer.
    Montenegro RC; Clark PG; Howarth A; Wan X; Ceroni A; Siejka P; Nunez-Alonso GA; Monteiro O; Rogers C; Gamble V; Burbano R; Brennan PE; Tallant C; Ebner D; Fedorov O; O'Neill E; Knapp S; Dixon D; Müller S
    Oncotarget; 2016 Jul; 7(28):43997-44012. PubMed ID: 27259267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MCM5 as a target of BET inhibitors in thyroid cancer cells.
    Mio C; Lavarone E; Conzatti K; Baldan F; Toffoletto B; Puppin C; Filetti S; Durante C; Russo D; Orlacchio A; Di Cristofano A; Di Loreto C; Damante G
    Endocr Relat Cancer; 2016 Apr; 23(4):335-47. PubMed ID: 26911376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acetylation of CCAR2 Establishes a BET/BRD9 Acetyl Switch in Response to Combined Deacetylase and Bromodomain Inhibition.
    Rajendran P; Johnson G; Li L; Chen YS; Dashwood M; Nguyen N; Ulusan A; Ertem F; Zhang M; Li J; Sun D; Huang Y; Wang S; Leung HC; Lieberman D; Beaver L; Ho E; Bedford M; Chang K; Vilar E; Dashwood R
    Cancer Res; 2019 Mar; 79(5):918-927. PubMed ID: 30643017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BET Inhibition Upregulates SIRT1 and Alleviates Inflammatory Responses.
    Kokkola T; Suuronen T; Pesonen M; Filippakopoulos P; Salminen A; Jarho EM; Lahtela-Kakkonen M
    Chembiochem; 2015 Sep; 16(14):1997-2001. PubMed ID: 26212199
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins.
    Lockwood WW; Zejnullahu K; Bradner JE; Varmus H
    Proc Natl Acad Sci U S A; 2012 Nov; 109(47):19408-13. PubMed ID: 23129625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bromodomain inhibitors, JQ1 and I-BET 762, as potential therapies for pancreatic cancer.
    Leal AS; Williams CR; Royce DB; Pioli PA; Sporn MB; Liby KT
    Cancer Lett; 2017 May; 394():76-87. PubMed ID: 28254412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unraveling the Role of Bromodomain and Extra-Terminal Proteins in Human Uterine Leiomyosarcoma.
    Yang Q; Falahati A; Khosh A; Lastra RR; Boyer TG; Al-Hendy A
    Cells; 2024 Aug; 13(17):. PubMed ID: 39273015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BET bromodomain inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma.
    Loganathan SN; Tang N; Fleming JT; Ma Y; Guo Y; Borinstein SC; Chiang C; Wang J
    Oncotarget; 2016 Jul; 7(28):43504-43517. PubMed ID: 27259270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BET bromodomain inhibitors--a novel epigenetic approach in castration-resistant prostate cancer.
    Lochrin SE; Price DK; Figg WD
    Cancer Biol Ther; 2014; 15(12):1583-5. PubMed ID: 25535892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of BET bromodomains alleviates inflammation in human RPE cells.
    Hytti M; Tokarz P; Määttä E; Piippo N; Korhonen E; Suuronen T; Honkakoski P; Kaarniranta K; Lahtela-Kakkonen M; Kauppinen A
    Biochem Pharmacol; 2016 Jun; 110-111():71-9. PubMed ID: 27106081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure-Activity Relationship Study of N(6)-Benzoyladenine-Type BRD4 Inhibitors and Their Effects on Cell Differentiation and TNF-α Production.
    Amemiya S; Yamaguchi T; Sakai T; Hashimoto Y; Noguchi-Yachide T
    Chem Pharm Bull (Tokyo); 2016; 64(9):1378-83. PubMed ID: 27581642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma.
    Hensel T; Giorgi C; Schmidt O; Calzada-Wack J; Neff F; Buch T; Niggli FK; Schäfer BW; Burdach S; Richter GH
    Oncotarget; 2016 Jan; 7(2):1451-63. PubMed ID: 26623725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epigenetic blockade of neoplastic transformation by bromodomain and extra-terminal (BET) domain protein inhibitor JQ-1.
    Zhang C; Su ZY; Wang L; Shu L; Yang Y; Guo Y; Pung D; Bountra C; Kong AN
    Biochem Pharmacol; 2016 Oct; 117():35-45. PubMed ID: 27520485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical evaluation of the BET bromodomain inhibitor BAY 1238097 for the treatment of lymphoma.
    Bernasconi E; Gaudio E; Lejeune P; Tarantelli C; Cascione L; Kwee I; Spriano F; Rinaldi A; Mensah AA; Chung E; Stathis A; Siegel S; Schmees N; Ocker M; Zucca E; Haendler B; Bertoni F
    Br J Haematol; 2017 Sep; 178(6):936-948. PubMed ID: 28653353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progress in the development of domain selective inhibitors of the bromo and extra terminal domain family (BET) proteins.
    Fu Y; Zhang Y; Sun H
    Eur J Med Chem; 2021 Dec; 226():113853. PubMed ID: 34547507
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stromal remodeling by the BET bromodomain inhibitor JQ1 suppresses the progression of human pancreatic cancer.
    Yamamoto K; Tateishi K; Kudo Y; Hoshikawa M; Tanaka M; Nakatsuka T; Fujiwara H; Miyabayashi K; Takahashi R; Tanaka Y; Ijichi H; Nakai Y; Isayama H; Morishita Y; Aoki T; Sakamoto Y; Hasegawa K; Kokudo N; Fukayama M; Koike K
    Oncotarget; 2016 Sep; 7(38):61469-61484. PubMed ID: 27528027
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biological and molecular effects of bromodomain and extra-terminal (BET) inhibitors JQ1, IBET-151, and IBET-762 in OSCC cells.
    Baldan F; Allegri L; Lazarevic M; Catia M; Milosevic M; Damante G; Milasin J
    J Oral Pathol Med; 2019 Mar; 48(3):214-221. PubMed ID: 30618144
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined inhibition of BET proteins and class I HDACs synergistically induces apoptosis in urothelial carcinoma cell lines.
    Hölscher AS; Schulz WA; Pinkerneil M; Niegisch G; Hoffmann MJ
    Clin Epigenetics; 2018; 10():1. PubMed ID: 29312470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.